ABT199中间体1

ABT199中间体1性质、用途与生产工艺

简介

ABT-199是国际癌症研究小组开发的一种新型抗癌药物，其有希望用于对抗癌症，比现有的可用于癌症治疗的药物副作用更小，疗效更快。ABT-199与普通癌症药物不同，是一新型药物，通过攻击一种被称作为BCL-2的重要蛋白起到治疗癌症的作用。ABT199中间体1为ABT199合成过程中的中间体。

用途

ABT199中间体1是合成对抗癌症药的ABT199的前体物质，可用作医药中间体。

用途

4-((2-(4-氯苯基)-4,4-二甲基-1-环己烯)甲基)哌嗪二盐酸盐是一种用于制备维奈托克（Venetoclax）的中间体，它是一种有效的选择性BCL-2抑制剂，具有强大的抗肿瘤活性，同时保留血小板。维奈托克（Venetoclax）用于治疗慢性淋巴细胞白血病细胞和雌激素受体阳性乳腺癌。

ABT199中间体1 上下游产品信息

上游原料

下游产品

ABT199中间体1 生产厂家

 

1628047-87-9, ABT199中间体1 相关搜索:

• 杂质对照品
• 化学试剂
• 原料
• C19H27ClN22ClH
• C19H29Cl3N2
• C19H27ClN22HCl
• 1-((4'-氯-5,5-二甲基-3,4,5,6-四氢-[1,1'-联苯]-2-基)甲基)哌嗪二盐酸盐
• 维奈克拉/维纳妥拉杂质23
• 维奈妥拉杂质31(盐酸盐)
• ABT199中间体1628047-87-9
• 1-[[2-(4-氯苯基)-4,4-二甲基-1-环己烯-1-基]甲基](哌嗪二盐酸盐ABT199中间体)
• 1-((4'-氯-5,5-二甲基-3,4,5,6-四氢-[1,1'-二苯基]-2-基)甲基)哌嗪二盐酸盐
• VENETOCLAX ABT-199 中间体1
• 1-((4'-氯-5,5-二甲基-3,4,5,6-四氢-[1,1'-联苯] -2-基)甲基)哌嗪二盐酸盐
• 1 - ((4'-氯-5,5-二甲基-3,4,5,6-四氢 - [1,1'-联苯] -2-基)甲基)
• 1-[[2-(4-氯苯基)-4,4-二甲基-1-环己烯-1-基]甲基]哌嗪二盐酸盐
• ABT199中间体1
• 4-((2-(4-氯苯基)-4,4-二甲基-1-环己烯)甲基)哌嗪二盐酸盐
• 1 - {[2-(4-氯苯基)-4,4-二甲基-1-环己烯-1-基]甲基}哌嗪二盐酸
• 1-[[2-(4-氯苯基)-4,4-二甲基环己-1-烯基]甲基]哌嗪盐酸盐
• 1-[[2-(4-氯苯基)-4,4-二甲基环己-1-烯基]甲基]哌嗪双盐酸盐
• 1-[[2-(4-氯苯基)-4,4-二甲基环己-1-烯基]甲基]哌嗪二盐酸盐
• ABT199中间体 1KG
• 1 - {[2-(4-氯苯基)-4,4-二甲基环己-1-烯-1-基]甲基}哌嗪二盐酸盐
• 1628047-87-9
• 1-((4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methy)piperazine dihydrochloride
• 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride
• 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen- yl]methyl]-piperazine,dihydrochlorid
• 1-((2-chlorophelyl)-4,4-diemethylcyclohex-1-en-1-yl)methyl)piperazine dihydrochloride
• Venetoclax Impurity 23 DiHCl
• Venetoclax Impurity 31(Hydrochloride)
• 1 - ((4 '- chloro-5,5-dimethyl-3,4,5,6-tetrahydro - [1,1' - diphenyl] - 2-yl) methyl) piperazine dihydrochloride
• 5-dimethyl-3
• 1-biphenyl]-2-yl)methyl)piperazine dihydrochloride
• 1-((4-chloro-5
• 1-[[2-(4-chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazine dihydrochloride
• Venetoclax Intermediate 2
• Piperazine, 1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]- (Dihydrochloride)
• ABT-199 Intermeidate1
• 1-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]piperazine diHCL
• 1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine hydrochloride
• 1-((4'-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydroch
• 1-((4-Chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine 2HCl
• 1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl] methyl]-Piperazine, hydrochloride (1:2)
• 1-{[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl}piperazine dihydrochloride
• 1-((4'-Chloro-5,5-dimethyl-3,4,5,6-tetrah ydro-[1,1'-biphenyl]-2-yl)methy)piperazine dihydrochloride
• Piperazine, 1-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-, hydrochloride (1:2)
• 1-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine dihydrochloride
• 1-((4'-chloro-5,5-demethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl-2yl]methyl)piperazine dihydrochloride
• 1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine dihydrochloride
• abt199 int 1
• ABT199 intermediate1
• 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine dihydrochloride